Phase I PHE885 CAR T-Cell
Phase I: BCMA-Targeted PHE885 CAR T-Cell Therapy With Rapid Manufacturing Time for R/R Multiple Myeloma

Released: June 09, 2023

Activity

Progress
1
Course Completed